详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Advances in magnetic resonance imaging contrast agents for glioblastoma-targeting theranostics.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ EI ◇ 卓越：高起点新刊

作者：

机构： [1]Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China [2]Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China [3]Department of Radiology, School of Medicine, Stanford University, Stanford, CA 94305, USA

出处：

DOI：

ISSN：

关键词： glioblastoma MRI targeted contrast agents therapy drug delivery

摘要：

Glioblastoma (GBM) is the most aggressive malignant brain tumour, with a median survival of 3 months without treatment and 15 months with treatment. Early GBM diagnosis can significantly improve patient survival due to early treatment and management procedures. Magnetic resonance imaging (MRI) using contrast agents is the preferred method for the preoperative detection of GBM tumours. However, commercially available clinical contrast agents do not accurately distinguish between GBM, surrounding normal tissue and other cancer types due to their limited ability to cross the blood-brain barrier, their low relaxivity and their potential toxicity. New GBM-specific contrast agents are urgently needed to overcome the limitations of current contrast agents. Recent advances in nanotechnology have produced alternative GBM-targeting contrast agents. The surfaces of nanoparticles (NPs) can be modified with multimodal contrast imaging agents and ligands that can specifically enhance the accumulation of NPs at GBM sites. Using advanced imaging technology, multimodal NP-based contrast agents have been used to obtain accurate GBM diagnoses in addition to an increased amount of clinical diagnostic information. NPs can also serve as drug delivery systems for GBM treatments. This review focuses on the research progress for GBM-targeting MRI contrast agents as well as MRI-guided GBM therapy.© The Author(s) 2021. Published by Oxford University Press.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区工程技术

小类 | 2 区材料科学：生物材料

最新[2023]版：

大类 | 1 区医学

小类 | 2 区材料科学：生物材料

第一作者：

第一作者机构： [1]Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China

共同第一作者：

通讯作者：

通讯机构： [1]Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China [*1]Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Advances in bacteria-based therapy for drug delivery [2]Polymer-drug and polymer-protein conjugated nanocarriers: Design, drug delivery, imaging, therapy, and clinical applications [3]Polydopamine-based nanomaterials and their potentials in advanced drug delivery and therapy. [4]Developments on the Smart Hydrogel-Based Drug Delivery System for Oral Tumor Therapy [5]Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects. [6]PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications. [7]Graphene/carbohydrate polymer composites as emerging hybrid materials in tumor therapy and diagnosis [8]Promising Nanomedicines of Shikonin for Cancer Therapy [9]Nanomedicine: Innovative Strategies and Recent Advances in Targeted Cancer Therapy [10]Customizing delivery nano-vehicles for precise brain tumor therapy